Product
ODM-201
3 clinical trials
2 indications
Indication
Prostate CancerClinical trial
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.Status: Terminated, Estimated PCD: 2021-06-28
Clinical trial
A Phase 2 Randomized Open-Label Study of Oral Darolutamide (ODM-201) vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-01-13
Clinical trial
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-01-31